JP2023546915A5 - - Google Patents
Info
- Publication number
- JP2023546915A5 JP2023546915A5 JP2023524275A JP2023524275A JP2023546915A5 JP 2023546915 A5 JP2023546915 A5 JP 2023546915A5 JP 2023524275 A JP2023524275 A JP 2023524275A JP 2023524275 A JP2023524275 A JP 2023524275A JP 2023546915 A5 JP2023546915 A5 JP 2023546915A5
- Authority
- JP
- Japan
- Prior art keywords
- solvate
- pharmaceutically acceptable
- acceptable salt
- compound according
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063094791P | 2020-10-21 | 2020-10-21 | |
| US63/094,791 | 2020-10-21 | ||
| PCT/IB2021/000723 WO2022084747A1 (en) | 2020-10-21 | 2021-10-20 | Compounds and methods for the treatment of ocular disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546915A JP2023546915A (ja) | 2023-11-08 |
| JP2023546915A5 true JP2023546915A5 (https=) | 2024-10-28 |
Family
ID=81290149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524275A Pending JP2023546915A (ja) | 2020-10-21 | 2021-10-20 | 眼障害を処置するための化合物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240158375A1 (https=) |
| EP (1) | EP4232458A4 (https=) |
| JP (1) | JP2023546915A (https=) |
| KR (1) | KR20230110514A (https=) |
| CN (1) | CN116670116A (https=) |
| AU (1) | AU2021363705A1 (https=) |
| CA (1) | CA3196180A1 (https=) |
| IL (1) | IL302175A (https=) |
| MX (1) | MX2023004539A (https=) |
| WO (1) | WO2022084747A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024134272A2 (en) * | 2022-12-20 | 2024-06-27 | Azura Ophthalmics Ltd. | Compounds and methods for the treatment of dermal and ocular disorders |
| WO2025012700A2 (en) * | 2023-07-07 | 2025-01-16 | Azura Ophthalmics Ltd. | Compositions and methods for the treatment of autoimmune disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828074D0 (en) * | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0127423D0 (en) * | 2001-11-15 | 2002-01-09 | Glaxo Group Ltd | Process |
| US8084620B2 (en) * | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| JP6752276B2 (ja) * | 2015-07-08 | 2020-09-09 | アクセロビジョン インコーポレイテッド | 眼炎症状態を処置する際に使用するための、インテグリンα４アンタゴニストを含む薬学的組成物 |
| JP7700045B2 (ja) * | 2019-04-18 | 2025-06-30 | アズーラ オフサルミックス エルティーディー． | 眼障害を処置するための化合物および方法 |
-
2021
- 2021-10-20 IL IL302175A patent/IL302175A/en unknown
- 2021-10-20 AU AU2021363705A patent/AU2021363705A1/en not_active Abandoned
- 2021-10-20 KR KR1020237016454A patent/KR20230110514A/ko active Pending
- 2021-10-20 WO PCT/IB2021/000723 patent/WO2022084747A1/en not_active Ceased
- 2021-10-20 CA CA3196180A patent/CA3196180A1/en active Pending
- 2021-10-20 JP JP2023524275A patent/JP2023546915A/ja active Pending
- 2021-10-20 MX MX2023004539A patent/MX2023004539A/es unknown
- 2021-10-20 CN CN202180086912.3A patent/CN116670116A/zh active Pending
- 2021-10-20 EP EP21882233.6A patent/EP4232458A4/en active Pending
- 2021-10-20 US US18/033,053 patent/US20240158375A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023546915A5 (https=) | ||
| JP2023546453A5 (https=) | ||
| JP2008522981A5 (https=) | ||
| JP2021513534A5 (https=) | ||
| RU2409562C2 (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| RU2010133903A (ru) | Способ и промежуточные соединения для получения производных 5-бифенил-4-ил-2-метилпентановой кислоты | |
| CA2536182A1 (en) | Macrocyclic peptides active against the hepatitis c virus | |
| JP2021524838A5 (https=) | ||
| JP2016509591A5 (https=) | ||
| JP2011219498A5 (https=) | ||
| JP2008509166A5 (https=) | ||
| JP2005533040A5 (https=) | ||
| HUP0300121A2 (hu) | A hepatitis C vírus ellen hatásos makrociklusos peptidek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| AR083161A1 (es) | Inhibidores macrociclicos de la replicacion del virus de la hepatitis c, composiciones farmaceuticas que los comprenden, su uso en medicamentos, intermediarios de su sintesis y metodos de preparacion de los mismos | |
| CA2475432A1 (en) | 2,4,6-triamino-1,3,5-triazine derivative | |
| RU2409572C2 (ru) | Новые производные 2-азетидинона в качестве ингибиторов всасывания холестерина для лечения гиперлипидемических состояний | |
| JP2016527277A5 (https=) | ||
| RU2007117765A (ru) | 1, 5-нафтиридиназолидиноны, обладающие cdk1 антипролиферативной активностью | |
| RU2014145819A (ru) | Бициклическое соединение | |
| JP2014505723A5 (https=) | ||
| ATE450499T1 (de) | Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten | |
| AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
| JP2009505960A5 (https=) | ||
| CO5580743A2 (es) | Piperidinas y piperazinas 3,4-disustituidas, 3,5- disustituidas y 3,4,5-sustituidas | |
| AR045962A1 (es) | Derivados de disulfuro, sulfuro, sulfoxido y sulfona de mononitrato de 1,4:3,6 - dianhidrohexitol; sus usos en composiciones farmaceuticas para el tratamiento de enfermedades cardiovasculares y metodos para su preparacion. |